Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Appili Therapeutics Inc APLIF


Primary Symbol: T.APLI

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.


TSX:APLI - Post by User

Comment by TheBearInTheWoodson Dec 30, 2020 11:37pm
257 Views
Post# 32201382

RE:We need to fast-track this and where is our contract.

RE:We need to fast-track this and where is our contract.

It is difficult to see through the Covid pump of the second quarter when everyone shifted from Cancer , Cronic Cough etc to Covid for the market impact. I know the Federal government has only invested in one therapeutic in Canada and that is LSALT peptide with Arch Biopartners. 


I traded Apli Early on cause of the money behind it, it was hard to stay interested when the Bloom Burton guys where on BNN and we're only pumping Apli in the see of therapeutics. Anyways best of luck, but after Covid all these plays will just go back to what they were before, once again why the Gov invested in Arch cause they were Acute kidney injury before Covid and it just so happens that Covid results in Kidney Inflammation.

<< Previous
Bullboard Posts
Next >>